Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.
Sponsor: AstraZeneca
Summary
This is a phase 1, open-label, PET trial. The study is designed to investigate the effect of AZD2389 on FAP occupancy in the liver in participants with advanced liver fibrosis.
Official title: A Phase 1, Open-label Positron Emission Tomography Trial to Assess Changes in Liver Uptake of [68Ga]Ga-FAPI-46 Following Oral Administration of Single Doses of AZD2389 to Patients With Advanced Liver Fibrosis (PECHORA).
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2025-05-26
Completion Date
2026-05-26
Last Updated
2026-02-19
Healthy Volunteers
No
Conditions
Interventions
AZD2389
Doses of AZD2389 will be administrated orally
PET scan and radioligand
PET scan and radioligand
Locations (2)
Research Site
Solna, Sweden
Research Site
Stockholm, Sweden